It is estimated that about 60% of all human cancers harbour gain-of-function (dominant negative) or loss-of-activity p53 mutations, whereas in the remaining cases the function of wild-type p53 is disrupted by additional mechanisms (Harris and Levine, 2005). Here, TP53 is linked to cancer.